Science
Glossary
Plain-language definitions for visitors reading our science pages.
- CHR-P / UHR
- Clinical high-risk / ultra-high-risk — research constructs identifying people with elevated risk of transitioning to psychosis relative to the general population. Not a diagnosis of schizophrenia.
- Attenuated psychotic symptoms
- Subthreshold psychotic-like experiences that may occur in CHR-P states; presence does not mean psychosis is inevitable.
- Transition to psychosis
- Conversion from a high-risk state to a frank psychotic disorder under study definitions. Rates vary by enrichment and setting.
- Estimand
- A precise description of the treatment effect a trial aims to estimate (who, what outcome, under what conditions).
- Proof of concept (PoC)
- An early clinical study designed to test whether a candidate shows a meaningful signal on pre-specified endpoints — not automatically a prevention trial.
- Bioavailability (BA)
- How much and how quickly a substance reaches the bloodstream. BA comparisons are not efficacy proof in CHR-P.
- NWPT-SM32300
- NWPharmaTech’s investigational CBD micellar-emulsion softgel candidate for this workstream (company materials describe 300 mg). Investigational — not an approved CHR-P medicine.
- Pharmaceutical sponsor
- The organisation accountable for clinical development, safety and regulatory strategy for a study programme.
- DeSci (as used here)
- Exploring decentralised-science tools and new capital communities to support research financing — without giving community votes over clinical decisions.